UNSPSC 51322102: D,l-methionine or racemethionine

This classification denotes a hepatoprotective agent with the molecular formula C5H11NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 73JWT2K6T3. The term d,l-methionine is a United States Adopted Name designation. D,l-methionine or racemethionine bears US NLM identifiers UMLS ID C0034504 and NCI Concept Code C84131. SMILES: CSCCC(C(=O)O)N.

UNSPSC 51322102 D,l-methionine or racemethionine is a Commodity code covering pharmaceutical supply for emergency medical services, public health programs, and multi-state cooperative purchasing. State and local governments use this code to procure specific medications and pharmaceutical products through a mix of municipal purchasing departments, state health agencies, and cooperative purchasing vehicles. The City of Tampa Fire Rescue, for example, recently solicited Advanced Life Support Medications through the city's purchasing department as a sealed-bid procurement; the Texas Health and Human Services Commission issued exploratory market intelligence on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by Minnesota's Office of State Procurement released a statewide RFP for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in multiple states including Oregon. These solicitations show state and local governments buying emergency-care drugs (such as Labetalol, Epinephrine, Adenosine, and Diltiazem), generic pharmaceuticals through wholesale-distribution channels, and exploring new direct-to-manufacturer contracting models to optimize pharmacy benefit administration.

Activity under the code concentrates in the South and Upper Midwest, with recent opportunities posted in Florida, Texas, and Minnesota. The City of Tampa's Advanced Life Support Medications bid (26P00188), posted April 24, 2026 with a April 8, 2026 deadline, sought four specific medication line items (370 units of Labetalol HCI 100mg, 1,810 units of Epinephrine 1:10,000, 330 units of Adenosine 6mg, 1,020 units of Diltiazem 25mg) with a $40,000 estimated value, a one-year term with two one-year renewal options, and a 5 percent bid discount available to certified Small Local Business Enterprises. MMCAP's generic pharmaceuticals RFP (S1070000015802), posted January 20, 2026 with a March 26, 2026 deadline, required vendors to supply products through three authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson) and structured evaluation weighting heavily on price competitiveness (75 percent), with a two-year contract term and optional MMCAP extensions. Both opportunities required compliance with FDA standards, OSHA Hazard Communication Standards, and cGMP certification; the Texas RFI for direct-to-manufacturer prescriptions (HHS0017013) was exploratory and did not commit funding or timelines.